Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Parallel 3 Group, Phase 3 Clinical Trial for a Comparative Evaluation With the Existing Treatments, Verify the Long-term Efficacy and Safety of the First Cell Treatment Using Hearticellgram-AMI in AMI Patients.

Trial Profile

A Multi-center, Open-label, Parallel 3 Group, Phase 3 Clinical Trial for a Comparative Evaluation With the Existing Treatments, Verify the Long-term Efficacy and Safety of the First Cell Treatment Using Hearticellgram-AMI in AMI Patients.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms RELIEF
  • Sponsors Pharmicell
  • Most Recent Events

    • 18 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 31 Dec 2020.
    • 01 Feb 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 14 Nov 2013 Planned end date changed from 1 Jan 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top